InterAx partners with Lundbeck to identify better pharmaceutical compounds

InterAx Biotech AG, a spin-off of the Paul Scherrer Institute PSI and ETH Zurich, based at PARK INNOVAARE, is building a proprietary systems biology platform to assist pharmaceutical companies with their drug discovery. Recently, the company has signed a collaboration agreement with Lundbeck A/S, successfully showing the value of their insights to the industry.

Lundbeck A/S is a global pharmaceutical company specializing in psychiatric and neurological disorders. For decades at the forefront of neuroscientific research, the Danish company is now partnering with InterAx Biotech AG, pioneer in computational pharmacology for drug discovery, from Villigen. Both companies will combine their expertise in the characterization of drug candidates for an undisclosed target.

Using mathematical models and simulations, InterAx technology platform addresses the complexity of drug-induced cellular signaling mechanisms. It can significantly improve the selection of lead molecules thanks to its ability to better predict drug safety and efficacy before costly and risky clinical trials. For the pharmaceutical industry, this equals savings of millions in the development of one drug. “We are delighted to assist Lundbeck in their quest to identify compounds with superior biological properties for their target receptor with our unique technology”, says Maria Waldhoer, CSO at InterAx.